Biomarker discovery with our industry partners
A better understanding of the biomarkers associated with the onset of autoimmune diseases and disease progression will enable more accurate diagnosis, and subsequently better patient stratification and treatment response prediction. We also understand that the application of such markers for companion diagnostics will become an industry requirement for successful drug development programs, approvals and reimbursement. As such, biomarker discovery is an area of ongoing focus for our team at Protagen.
Driving discovery through research and development
Within our own R&D programs, we have successfully performed a broad range of proof of concept studies using disease specific biomarker panels for Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ankylosing Spondylitis, Systemic Sclerosis, Multiple Sclerosis and Neuromyelitis Optica. This portfolio of assays continues to grow in collaboration with a large number of clinical experts and medical centers throughout the world.
Our work identifying new response prediction markers using our SeroTag® biomarker identification and development engine has demonstrated the wealth of new opportunities we can offer our industry partners for co-developing CDx alongside new drugs for autoimmune diseases.